OINDPnews


Proveris Scientific

News

Philip Canner joins Cambridge Healthcare Innovations as CEO

Device developer Cambridge Healthcare Innovations (CHI) has announced the appointment of former AuroScience Head of Device Development Philip Canner as CEO. In addition to AuroScience, an Aurobindo subsidiary that develops generic inhaled drugs, Canner's OINDP development experience also includes a stint at Team Consulting. Earlier this year, CHI partnered with … [Read more...] about Philip Canner joins Cambridge Healthcare Innovations as CEO

Beckley Psytech initiates Phase 1 trial of intranasal 5-MeO-DMT

Beckley Psytech said that it has initiated dosing in a Phase 1 trial of its intranasal 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a psychedelic compound found in the secretions of certain toads. The company is developing the intranasal formulation for the treatment of treatment resistant depression (TRD). The single ascending dose study is expected to enroll up … [Read more...] about Beckley Psytech initiates Phase 1 trial of intranasal 5-MeO-DMT

ReCode Therapeutics raises $80 million for development of inhaled therapies for CF, PCD

ReCode Therapeutics has raised $80 million in Series B financing that it will use in large part to fund clinical development of inhaled therapies for cystic fibrosis and primary ciliary dyskinesia (PCD), the company said. According to the announcement, funds will also be used for expanding the company's pipeline and for adding manufacturing capabilities. Earlier … [Read more...] about ReCode Therapeutics raises $80 million for development of inhaled therapies for CF, PCD

Synairgen gets recommendation to advance its inhaled interferon for mild to moderate COVID-19 into Phase 3

According to Synairgen, the external data safety monitoring board (DSMB) for the ACTIV-2 study of the company's SNG001 nebulized interferon beta in mild to moderate COVID-19 patients has recommended that the company advance SNG001 into Phase 3. Synairgen said that it has not yet received any data from the ACTIV-2 trial. A Phase 3 trial of SNG001 in hospitalized … [Read more...] about Synairgen gets recommendation to advance its inhaled interferon for mild to moderate COVID-19 into Phase 3

Shandong Luoxin gets Chinese rights to Marinomed’s Budesolv budesonide nasal spray

Shandong Luoxin Pharmaceutical will pay $2 million up front plus milestone payments of up to $20 million to acquire exclusive rights to develop, manufacture, and commercialize Marninomed's Budesolv budesonide nasal spray in China, the company has announced. In April 2019, Marinomed announced that a Phase 3 trial of Budesolv for the treatment of allergic rhinitis had … [Read more...] about Shandong Luoxin gets Chinese rights to Marinomed’s Budesolv budesonide nasal spray

Aptar Pharma to co-develop i2c’s Respitab MDI technology

Aptar Pharma will co-develop and promote i2c Pharmaceutical Services' Respitab MDI technology, the two companies have announced. The Respitab system involves formulating the drug as a tablet that can be easily dispensed into an MDI canister; the tablet is then dissolved or dispersed when the can is filled with propellant. According to the announcement, Aptar will … [Read more...] about Aptar Pharma to co-develop i2c’s Respitab MDI technology

Immune Biosolutions initiates Phase 1 trial of IBIO123 inhaled antibody therapy

Canadian Biotech Immune Biosolutions said it has initiated a Phase 1 clinical trial of its IBIO123 inhaled antibody therapy, which it is developing for the treatment of COVID-19. According to the company, the trial is being conducted in South Africa and will evaluate IBIO123 versus placebo in patients with symptomatic COVID-19. Earlier this year, the Canadian … [Read more...] about Immune Biosolutions initiates Phase 1 trial of IBIO123 inhaled antibody therapy

Biosidus partners with Crystec on development of dry powder teriparatide for the treatment of osteoporosis

Argentinian pharma company Biosidus and Crystec have announced a new deal for development of dry powder formulations of Biosidus drugs for inhaled and/or nasal delivery using Crystec's mSAS supercritical fluid particle engineering technology. The first project for the two companies under the new agreement will be development of a dry powder formulation of teriparatide … [Read more...] about Biosidus partners with Crystec on development of dry powder teriparatide for the treatment of osteoporosis